MEDomics is a privately held molecular diagnostics company that was founded in 2008 with the mission to provide Mutation Expert- based Diagnosis (“MED”) of a patient’s genome to better allow the physician to deliver personalized treatment. MEDomics was founded by Dr. Steve Sommer MD, PhD, FACMG, a founding member of the American College of Medical Genetics and a pioneer in the analysis of genetic variants that cause disease. MEDomics provides genomic solutions for the diagnosis of the Mi IDEA Diseases: Mitochondrial disease, Intellectual Disability, Epilepsy, and Autism using Next Generation Sequencing methodology and custom proprietary bioinformatics pipelines for variant analysis that yield perhaps the most in-depth clinical reports in the industry. Our dedicated team uses bioinformatics, clinical genetics, and mutation analysis to provide high quality interpretations of genome data, which can lead to improved diagnosis, treatment, and prevention of human disease. MEDomics has been recognized as the first lab focused on CLIA Clinical Next Generation (NextGen) DNA sequencing for clinical diagnostic testing. The testing is integrated with personalized medicine. Biochemical weaknesses are defined to generate sometimes transforming personalized diet and or personalized drug therapy.